Results 181 to 190 of about 1,951,570 (332)

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Hidden translocation between 15qter and 18qter impressed during cycles of preimplantation genetic testing using linkage analyses and chromosome microarray subsequently verified by fluorescence in situ hybridization

Gwo-Chin Ma, Chi-Fang Lin, Wen-Hsiang Lin, Shun-Ping Chang, Dong-Jay Lee, Mei-Hui Lee, Yi-Shing Lin, Ming Chen   +7 more
openalex   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Global Perspectives on Genetic Testing Among Nephrologists. [PDF]

Kidney Int Rep
George J, Vachharajani T, Wang X.
europepmc   +1 more source

Prospective Feasibility Trial of a Novel Strategy of Facilitated Cascade Genetic Testing Using Telephone Counseling [PDF]

, 2020
Melissa K. Frey, Ryan Kahn, Eloise Chapman‐Davis, F. Tubito, Maira M. Pires, Paul J. Christos, Samantha Anderson, Semanti Mukherjee, B. Jordan, Stephanie V. Blank, Thomas A. Caputo, Ravi Sharaf, Kenneth Offit, Kevin Holcomb, Steven M. Lipkin   +14 more
openalex   +1 more source

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source

Retraction: Genetic Testing for Successful Cancer Treatment. [PDF]

Cureus
Singh DN, Daripelli S, Elamin Bushara MO, Polevoy GG, Prasanna M.   +4 more
europepmc   +1 more source

Disparities in Genetic Testing for Neurologic Disorders [PDF]

Aaron Baldwin, J. Nathan Copeland, Meron Azage, Laynie Dratch, Kelsey Johnson, Rachel Paul, Defne A. Amado, Michael Baer, Andres Deik, Lauren Elman, Michael H. Guo, Ali G. Hamedani, David J. Irwin, A. G. Lasker, Jennifer Orthmann‐Murphy, Colin Quinn, Thomas F. Tropea, Steven S. Scherer, Russell T. Shinohara, Roy H. Hamilton, Colin A. Ellis   +20 more
openalex   +1 more source

Body composition and blood pressure in 6-year-old singletons born after pre-implantation genetic testing for monogenic and structural chromosomal aberrations: a matched cohort study [PDF]

, 2018
Florence Belva, Mathieu Roelants, Salome Adriana Kluijfhout, C. Winter, F. De Schrijver, S. Desmyttere, Martine De Rycke, Herman Tournaye, I. Liebærs, M Bonduelle   +9 more
openalex   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source